Eribulin
- Generic Name
- Eribulin
- Brand Names
- Halaven, Eribulin Baxter, Mevlyq
- Drug Type
- Small Molecule
- Chemical Formula
- C40H59NO11
- CAS Number
- 253128-41-5
- Unique Ingredient Identifier
- LR24G6354G
- Background
Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid ...
- Indication
For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.
- Associated Conditions
- Metastatic Liposarcoma, Refractory, metastatic Breast cancer, Unresectable Liposarcoma
- Associated Therapies
- -
JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC
- Conditions
- Interventions
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 40
- Registration Number
- NCT06731153
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast CarcinomaLocally Advanced HER2-Negative Breast CarcinomaLocally Advanced Hormone Receptor-Positive Breast CarcinomaLocally Advanced Triple-Negative Breast CarcinomaMetastatic HER2-Negative Breast CarcinomaMetastatic Hormone Receptor-Positive Breast CarcinomaMetastatic Triple-Negative Breast CarcinomaUnresectable HER2-Negative Breast Carcinoma
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT06590558
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center LAO, Columbus, Ohio, United States
Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-06
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Wang Jiayu
- Target Recruit Count
- 60
- Registration Number
- NCT06539559
- Locations
- 🇨🇳
Beijing Chaoyang District San Huan Cancer Hospital, Beijing, Beijing, China
🇨🇳Cancer Hospital of HuanXing ChaoYang District, Beijing, Beijing, China
🇨🇳Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2024-07-25
- Target Recruit Count
- 350
- Registration Number
- NCT06519370
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 70
- Registration Number
- NCT06449222
- Locations
- 🇺🇸
Saint John's Health Center - John Wayne Cancer Institute (JWCI), Santa Monica, California, United States
🇺🇸Carle Foundation Hospital d/b/a Carle Cancer Center, Urbana, Illinois, United States
🇺🇸Bozeman Health Deaconess Hospital Cancer Center, Bozeman, Montana, United States
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 550
- Registration Number
- NCT06435429
- Locations
- 🇺🇸
USC-Norris Comprehensive Cancer Center - Investigational Drug Service IDS, Los Angeles, California, United States
🇺🇸Medstar Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸Washington Cancer Center, Washington, District of Columbia, United States
LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 74
- Registration Number
- NCT06387628
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 436
- Registration Number
- NCT06382142
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 382
- Registration Number
- NCT06343948
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
ELVN-002 with Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Enliven Therapeutics
- Target Recruit Count
- 275
- Registration Number
- NCT06328738
- Locations
- 🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇧🇪CHU de Liège, Liège, Belgium
🇧🇪GZA Ziekenhuizen - Campus Sint-Augustinus, Wilrijk, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.